
Named Patient Program (NPP) by Ikris Pharma Network facilitates legal, prescription-gated import of specialty and rare-disease medicines not yet approved or available in India.
Named Patient Program (NPP), part of Ikris Pharma Network, enables patients and healthcare providers in India to legally access specialty medicines - primarily oncology, hematology, rare disease, and other high-cost biologics - that are approved abroad but not yet available in India. NPP manages the full process: compliance and prescription document review, transparent pricing and timelines, regulatory approvals, and GDP-compliant cold-chain delivery across ambient, refrigerated, and frozen temperature ranges with 24/7 monitoring. NPP does not manufacture medicines; it sources directly from manufacturers and authorized distributors, and coordinates import under India's Named Patient Program regulatory pathway. The site catalogues over 200 specialty drugs across therapeutic areas including oncology, rare disease, endocrinology, pulmonology, neurology, nephrology, immunology, hepatology, and cardiology, helping patients and doctors navigate legal access to critical therapies not yet launched domestically.
2017
Company Incorporation
Ikris Pharma Network Pvt Ltd was incorporated, later establishing Named Patient Program to facilitate legal import of specialty medicines for Indian patients.
B2B
Hospitals, oncologists, and specialty clinics in India seeking legal access to imported medicines not yet available domestically for their patients.
Client Segment
:
HealthTech / MedTech / Healthcare,
Life Sciences
Target Companies
:
Small Enterprise,
Medium Enterprise,
Large Enterprise
Target Geography
:
B2C
Patients and families in India needing legal, prescription-gated access to specialty medicines not yet approved or available domestically.
User Age
:
Less than 18,
18 to 25,
26 to 34,
35 to 45,
46 to 60
User Income
:
Upper-middle Income,
High Income
Location
:
Frequently Asked Questions